Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Current Medical Research and Opinion|September 25, 2014
Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteersAnton Buchner, Andreas Lammerich, Afsaneh Abdolzade-Bavil, et al.Methods in Molecular Biology (Clifton, N.J.)|August 21, 2012
Assessing heterogeneity of peroxisomes: isolation of two subpopulations from rat liverMarkus Islinger, Afsaneh Abdolzade-Bavil, Sven Liebler, et al.Proteomics|June 10, 2004
Convenient and versatile subcellular extraction procedure, that facilitates classical protein expression profiling and functional protein analysisAfsaneh Abdolzade-Bavil, Scott Hayes, Lothar Goretzki, et al.Bioanalysis|February 5, 2021
Assay concept for detecting anti-drug IgM in human serum samples by using a novel recombinant human IgM positive controlChristian Künzel, Afsaneh Abdolzade-Bavil, Alfred M Engel, et al.Bioanalysis|September 29, 2017
Method establishment for discerned immunogenicity assessment of a recombinant glycoprotein containing nonhuman sialic acid Neu5Gc residuesMarc-Olivier Montjovent, Linglong Zou, Heinrich Faust, et al.Bioanalysis|April 12, 2018
Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injectionUwe Wessels, Markus Zadak, Astrid Reiser, et al.Frontiers in Pharmacology|September 15, 2022
Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administrationArthur J Van De Vyver, Antje-Christine Walz, Mariette S Heins, et al.Journal of Clinical Pharmacology|June 25, 2015
Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profileAfsaneh Abdolzade-Bavil, Aaron von Kerczek, Bridget A Cooksey, et al.Clinical Pharmacology and Therapeutics|May 21, 2024
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting AntibodySara Belli, Maria Amann, Lucy Hutchinson, et al.Journal of Pharmaceutical Sciences|December 6, 2025
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIIIElisabeth Husar, Silke Simon, Afsaneh Abdolzade-Bavil, et al.Pageof 2